The nutritional support from the radiation oncologist point of view

Isacco Desideri Università di Firenze AOUM-AOUC





Introduction

Radiation therapy is one of the primary modalities for treating malignant diseases and is used in both curative and palliative settings for almost all solid tumors.


With few exceptions(TBI), is a loco-regional therapy, with toxicities related to the site of irradiation

Approximately 60% of cancer patients will receive a radiation treatment during their lifetime


Modern advances in radiotherapy (IMRT, SABR, SRS,IGRT, MRI-linac, Protons) allow radoncs to better spare organs at risk

Toxicities are nonetheless a concern, especially in patients receiving concomitant systemic treatement (e.g. chemotherapy; immunotherapy)


The evolution of radiotherapy: from 2D to IMRT



Advantages of modern radiation techniques



Pathophysiology of RT effects on normal tissue



Mucositis

Management through analgesics, oral hygiene, treatment of infections, proton pump inhibitors (oesophagitis) and maintenance of nutritional intake

Radiation dermatitis

Management through hydrating ointments, topical steroids, no sun exposure and, in severe cases, local therapy as in burns

Cystitis

Management through NSAIDs for irritative voiding symptoms, anticholinergics and/or antispasmodics for cystitis or bladder spasm and cranberry juice or urinary alkalizers for dysuria and treatment of infections

Neurological

Management through corticoisteroids (oedema) and anti-epileptic drugs

Respiratory

Management through bronchodilatation, treatment of infections and judicious use of corticosteroids

Cardiac

Management through acetylsalicylic acid and colchicine (acute effusion), anti-arrhythmia drugs and treatment of heart failure

Gastrointestinal

Management through appropriate diet, anti-diarrhoea treatments and treatment of infection and malabsorption

General overview of RT acute toxicities

De Ruysscher et al. Nat Rev 2019


Nutritional therapy: Main focus for a Radiation Oncologist


Head and Neck

malignancies




Gastrointestinal malignancies





Thorax malignancies




Mucositis

Radiotherapy to the head and neck or esophagus induces mucositis, decreased food intake, and weight loss in up to 80% of patients


Similarly, radiotherapy of the pelvic region is associated with GI symptoms in up to 80% of patients

Pathobiology phases of RT-induced oral mucositis




Maria et al. 2017


Impact of eccessive toxicity on OS in the era of chemoradiotherapy for SCCHN



Proposed interventions for balancing mucositis impact on patients' outcome



Dysphagia: from SWOARs to Functional Units



Shaikh et al. IJROBP 2016

Dysphagia impact on SCCHN patients

A common, multifactorial, and debilitating sequela for patients who undergo definitive (chemo)radiotherapy for head and neck cancer

Involves a mixture of both acute and late toxicity mechanism


Contribute to **significant survivorship burden** for SCCHN patients

Also detrimental impacts on the psychosocial aspects of and participation in everyday life and ultimately reduced quality of life Potential pitfalls in managing weight loss in the IMRT era

Baseline / 7700.0 / 4500.0 ✓ 3500.0 **√ 2000.0** Week 5: after ART Week 5: before ART В

ADAPTIVE RADIOTHERAPY

Morgan et al. 2020




ESPEN guidelines 2021

	Selection bias – random sequence generation	Selection bias – allocation concealment	Reporting bias – selective reporting	Other bias – other sources of bias	Performance bias – blinding (participant and personnel)	Detection bias – blinding (outcome assessment)	Attrition bias – incomplete outcome data	Overall risk of- bias judgement
Boisselier 2020	low	low	low	low	low	low	low	Low risk
Chao 2020	Non-RCT - retrospective study							
Chitapanarux 2019	low	low	low	low	high	unclear	low	Some concerns
Harada 2019	unclear	unclear	low	low	high	unclear	low	High risk
Chitapanarux 2016	low	low	low	low	high	unclear	low	Some concerns
Yuce Sari 2016	Non-RCT – comparative cohort study							
Vasson 2014	low	low	low	low	low	low	high	Low risk
Roca-Rodriguez 2014	unclear	unclear	low	low	high	unclear	low	High risk
Fietkau 2013	low	low	low	low	low	low	high	Some concerns
Yeh 2013	low	low	low	low	high	low	low	Low risk
Huang 2019	low	low	low	low	low	low	high	Low risk
Pathak 2019	low	low	low	low	high	unclear	low	Some concerns
Akmansu 2018	Non-RCT - retrospective study							
Pachon Ibanez 2018	Non-RCT – comparative cohort study							
Lopez-Vaquero 2017	low	low	low	low	low	low	low	Low risk
Pattanayak 2016	low	low	low	low	unclear	low	low	Low risk
Tsujimoto 2015	low	low	low	low	low	low	high	Low risk
Imai 2014	unclear	unclear	low	low	low	low	high	High risk
Chattopadhyay 2014	unclear	unclear	low	low	high	low	low	High risk

Immunonutrion in HN patients


- Systematic review
- 20 studies; 15 RCT
- 1535 patients
- Reasonable QoE
- Favourable impact on OS with immunonutrion

Nutritional status as a predictor of RT toxicity



- 100 pts w/ esophageal cancer
- Nutritional status assessed pre-RT:
 - PG-SGA
 - WL
 - ALB
 - Hb
- Baseline nutritional status associated with development of grade ≥2 radiation esophagitis


Influence of nutrional status in locally advanced rectal cancer patients



Time (months)

- Neoadjuvant RTCT is a mainstay in LARC patients
- 93 LARC older patients assessed
- Geriatric nutrional index (GNI): 1.489 × albumin (g/l) + 41.7 × current weight/ideal weight
- GNI was a good independent prognosticator in this cohort of patients

Ide et al. WJSO 2021



The quest for obtaining high-level evidence

- Study protocol
- ONS vs Traditional diet
- 25 patients per
- RCT assessing the benefit on ONS in esophageal cancer patients undergoing CRT

Chen et al. Medicine 2021

Conclusions

Nutrition intervention and management should begin before treatment, especially for patients with high risk factors

Nutritional status should be improved before anti-tumor treatment, especially in the cohort of patients pre-identified at high risk of malnutrion

A multidisciplinary approach, more than ever within this context, is of paramount importance to correctly manage the therapeutical process of these patients undergoing complex treatments involving radiotherapy, systemic therapy and surgery.





Collaborative Group NutriOnc Research Group

perchè insieme è meglio





Associazione Italiana Radioterapia Oncologica





Partecipanti alla Survey Dato complessivo

